

## **AMENDMENTS TO THE CLAIMS**

1. (Previously Presented) A pharmaceutical composition comprising an oil-in-water emulsion containing a prostaglandin F<sub>2α</sub> derivative, which is at least one member selected from the group consisting of latanoprost, isopropyl unoprostone, travoprost and bimatoprost, an oil, a water-soluble polymer and water.
2. (Canceled)
3. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the prostaglandin F<sub>2α</sub> derivative is latanoprost.
4. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the water-soluble polymer is at least one member selected from the group consisting of a polyvinyl compound, a water-soluble cellulose compound and a polysaccharide.
5. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the water-soluble polymer is polyvinyl alcohol.
6. (Original) The pharmaceutical composition according to claim 1, wherein the oil is an animal or vegetable oil, and/or medium chain fatty acid triglyceride.
7. (Canceled)
8. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an ophthalmological composition.
9. (Original) The pharmaceutical composition according to claim 8, wherein the ophthalmological composition is an eye drop.

10. (Previously Presented) An eye drop which is an oil-in-water emulsion, comprising latanoprost, medium chain fatty acid triglyceride, polyvinyl alcohol and water.
11. (Withdrawn - Previously Presented) A method of suppressing degradation of a prostaglandin F<sub>2α</sub> derivative in an emulsion, comprising blending a prostaglandin F<sub>2α</sub> derivative, an oil, a water-soluble polymer and water to form an oil-in-water emulsion.
12. (Withdrawn) A method of suppressing degradation of latanoprost in an emulsion, comprising blending latanoprost, Miglyol, polyvinyl alcohol and water to form an oil-in-water emulsion.